Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Additional information

The genetic toxicology assessment of Alchisor TAL 111 is based on read-across data from C9-C14 aliphatics (2-25% aromatics).

 

Negative results were given in in vitro bacterial gene mutation assays, in vitro cytogenetics assay, in vitro mammalian cell gene mutation assay and sister chromatid exchange assays. In addition negative results were given in two micronucleus and an in vivo cytogenetics assay. In addition an in vivo dominant-lethal inhalation study was negative for mutagenicity.

 


Justification for selection of genetic toxicity endpoint
No study was selected since all the in vitro and in vivo studies were negative.

Short description of key information:
The available genetic toxicology studies, both in vitro and in vivo, all gave a negative result.








In Vitro

C9-C14 aliphatic hydrocarbons (2-25% aromatics)
Ames test (DHC 1984a. Report No. 84/BP0004-011/245 [Hydrocarbons, C11-C14, n alkanes, isoalkanes, cyclics, aromatics (2-25%)]), negative.

In vitro mammalian chromosome aberration test (DHC 1984b. Report No. 84/BP0004-011/245 [Hydrocarbons, C11-C14, n-alkanes, isoalkanes, cyclics, aromatics (2-25%)]), negative.

In Vitro Sister Chromatid Exchange Assay in Mammalian Cells “read across” (API 1987. [Hydrodesulfurized kerosene]), negative.



In Vivo

C9-C14 aliphatic hydrocarbons (2-25% aromatics)
Mammalian bone marrow chromosome aberration test “read across” (Gochet 1984. [White Spirits]), negative.
Mammalian Erythrocyte Micronucleus Test “read across” (McKee 1994. [Turbo Fuel A]), negative.

Endpoint Conclusion: No adverse effect observed (negative)

Justification for classification or non-classification

Based on the available read-across data, the substance does not meet the criteria for classification.